INVEN2 AS
Inven2 - Innovasjon innen forskning og utvikling - Kliniske studier
Inven2 omgjør forskning og kunnskap til samfunnsnyttige produkter og tjenester. Inven2 sin kjernevirksomhet er innovasjon.
Keywords
researchdevelopment workbiotechnologygenomicspharmageneticsgene samplesdna sequencingdna synthesisdna deepeninggenetic engineeringproteinsmoleculespeptide sequencinglipidglycotechniqueproteomicshormonesgrowth factorscell receptorspheromonescell culturetissue culturecrossingcell fusionvaccineimmunostimulatorsembryo manipulationprocess biotechnologybioreactorsfermentationbioprocessingbiorecoverybiodesulfurizationbiological pulp productionbiofiltrationbiological regenerationsubcellular organismsgene therapyvirusesvectors
Organization
- CEO
- OK
- Chairman of the board
- TE
Tom Edward Pike1960
- Years since formation
- 14 years
- since May 15, 2010
- Type
- Limited company
- VAT registered
- Yes
- Number of employees
- 32
Ownership
- Number of shares and share classes
- 10,000
- 1 share class
- Total number of shareholders
- 2
- companies
- Belongs to group of
Financials
- Total operating income 2023
- 81,985,000
- NOK
- Annual total result 2023
- -2,245,000
- NOK
- Total equity 2023
- 193,575,000
- NOK
Last update: Aug 29, 2024
Management
Management / administration
| Name | Role | Shares |
|---|---|---|
OK | Managing Director/CEO | - |
Board
| Name | Role | Shares |
|---|---|---|
TE 1960 | Chairman | - |
RA | Board Member | - |
IS 1953 | Board Member | - |
PM | Board Member | - |
EB | Board Member | - |
IK 1962 | Board Member | - |
LK | Board Member | - |
| Board Member | - | |
NH | Board Member | - |
Others
| Name | Role | Shares |
|---|---|---|
| Auditor | - |
Last update: Jun 27, 2023
Ownership
Company shareholders
| Name | Share class | Number of shares | Share |
|---|---|---|---|
| Ordinary shares | 5,000 | 50 % | |
| Ordinary shares | 5,000 | 50 % |
Shares owned by the INVEN2 AS
| Name | Share class | Number of shares | Share |
|---|---|---|---|
| Ordinary shares | 30,000 | 100 % | |
| Ordinary shares | 30,000 | 100 % | |
| Ordinary shares | 20,000 | 66.67 % | |
| Ordinary shares | 50,000 | 50 % | |
| Ordinary shares | 117,861 | 41.04 % | |
| Ordinary shares | 45,000 | 39.09 % | |
| Ordinary shares | 10,585 | 35.28 % | |
| Ordinary shares | 34,300 | 33.46 % | |
| G-shares | 30,000 | 33.33 % | |
| Ordinary shares | 21,322 | 32.01 % | |
| Ordinary shares | 181,400 | 25.28 % | |
| Ordinary shares | 60 | 20 % | |
| Ordinary shares | 30,000 | 20 % | |
| Ordinary shares | 20,000 | 20 % | |
| Ordinary shares | 30,000 | 20 % | |
| Ordinary shares | 2,040,903 | 14.97 % | |
| NO0010754757 | 48,333 | 13.76 % | |
| Class B shares | 5,000 | 12.5 % | |
| NO0010820731 | 1,470,466 | 12.13 % | |
| Ordinary shares | 15,000 | 11.66 % | |
| Ordinary shares | 48,413 | 11.01 % | |
| Ordinary shares | 111 | 9.99 % | |
| NO0010891310 | 258,547 | 6.78 % | |
| Ordinary shares | 41,572 | 6.32 % | |
| Ordinary shares | 13,533 | 5.83 % | |
| Ordinary shares | 2,648 | 5.78 % | |
| NO0010858343 | 3,409 | 5.12 % | |
| Ordinary shares | 8,877 | 5.02 % | |
| Ordinary shares | 17,760 | 4.46 % | |
| Ordinary shares | 4,444 | 4 % | |
| NO0010851603 | 1,372,163 | 3.99 % | |
| Ordinary shares | 387,214 | 3.31 % | |
| NO0010162266 | 27,432 | 3.3 % | |
| Ordinary shares | 103,448 | 3.27 % | |
| NO0010848534 | 111,054 | 3.03 % | |
| Ordinary shares | 900 | 3 % | |
| Ordinary shares | 900 | 3 % | |
| Ordinary shares | 900 | 3 % | |
| Ordinary shares | 9,000 | 3 % | |
| Ordinary shares | 3,000 | 3 % | |
| Ordinary shares | 3,315,466 | 2.1 % | |
| NO0010722283 | 1,441,670 | 1.38 % | |
| Ordinary shares | 4,913 | 1.12 % | |
| NO0010779341 | 210,261 | 1.08 % | |
| H-shares | 3,356 | 0.55 % | |
| Ordinary shares | 900 | 0.43 % | |
| NO0010597883 | 541,247 | 0.23 % | |
| NO0010733454 | 3,396 | 0.18 % |
Last update: May 24, 2024
Group structure
- Total operating income 2023: NOK 81,985,000Operating profit 2023: NOK -17,826,000Employees: 32
Financials
in NOK
Summary
| Year | 2023 | 2022 | 2021 |
|---|---|---|---|
Total operating income | 81,985,000 | 158,267,000 | 110,272,000 |
Annual Total Result | -2,245,000 | 54,373,000 | 18,608,000 |
Total assets | 357,761,000 | 361,179,000 | 293,288,000 |
Total liabilities | 164,186,000 | 165,359,000 | 151,841,000 |
Total equity | 193,575,000 | 195,820,000 | 141,447,000 |
P&L
| Year | 2023 | 2022 | 2021 |
|---|---|---|---|
Total operating income | 81,985,000 | 158,267,000 | 110,272,000 |
Total operating costs | 99,811,000 | 90,840,000 | 99,968,000 |
Operating result | -17,826,000 | 67,428,000 | 10,304,000 |
Financial income/costs | 17,675,000 | -6,898,000 | 4,630,000 |
Profit before tax | -151,000 | 60,530,000 | 14,934,000 |
Total tax & extraordinary income/cost | 2,094,000 | 6,157,000 | -3,674,000 |
Annual Total Result | -2,245,000 | 54,373,000 | 18,608,000 |
Balance overview
| Year | 2023 | 2022 | 2021 |
|---|---|---|---|
Total fixed assets | 118,647,000 | 113,744,000 | 116,988,000 |
Total current assets | 239,114,000 | 247,435,000 | 176,301,000 |
Total assets | 357,761,000 | 361,179,000 | 293,288,000 |
Short term debt | 93,629,000 | 88,683,000 | 78,813,000 |
Long term debt | 0 | 0 | 0 |
Total liabilities | 164,186,000 | 165,359,000 | 151,841,000 |
Contributed capital | 40,000,000 | 40,000,000 | 40,000,000 |
Retained earnings | 153,575,000 | 155,820,000 | 101,447,000 |
Total equity | 193,575,000 | 195,820,000 | 141,447,000 |
Total equity and liabilities | 357,761,000 | 361,179,000 | 293,288,000 |
Classification
Type of organization
Limited company
Classification of institutional sector
INNL
Domestic sectors
A_IKKE-FIN
Non-financial corporations
1120
Public incorporated enterprises, owned by central government
Standard industrial classification
M
Main industrial area
Professional, scientific and technical activities
72
Activity
Scientific research and development
72.1
Main industrial group
Research and experimental development on natural sciences and engineering
72.11
Industrial group
Research and experimental development on biotechnology
72.110
Industrial group
Research and experimental development on biotechnology